AML with RUNX1::RUNX1T1 Cooperating two Mutations Relapsed Quickly after Achieving CR

XinhongYang; Yingwei Wu; Xiaofeng Yang; Xue Wu; Yingying Chen; Rongjuan Zhang; Zhihua Zhang

doi:10.7754/Clin.Lab.2023.230923

AML with RUNX1::RUNX1T1 Cooperating two Mutations Relapsed Quickly after Achieving CR

Clin Lab. 2024 Mar 1;70(3). doi: 10.7754/Clin.Lab.2023.230923.

Authors

XinhongYang, Yingwei Wu, Xiaofeng Yang, Xue Wu, Yingying Chen, Rongjuan Zhang, Zhihua Zhang

PMID: 38469780
DOI: 10.7754/Clin.Lab.2023.230923

Abstract

Background: Acute myeloid leukemia (AML) with t(8;21)(q22;q22.1); RUNX1::RUNX1T1 has a relatively favorable prognosis with a high complete remission rate and long disease-free survival.

Methods and results: Here we describe a patient who had AML with t(8;21)(q22;q22.1); RUNX1::RUNX1T1. Cooperating mutations including KRAS and ASXL1, and with other abnormal karyotype del(17) and with a myelomonocytic differentiation.

Conclusions: The patient relapsed despite achieving a morphologic complete remission (CR).

Publication types

Case Reports

MeSH terms

Core Binding Factor Alpha 2 Subunit / genetics
Humans
Leukemia, Myeloid, Acute* / genetics
Mutation
RUNX1 Translocation Partner 1 Protein / genetics
Translocation, Genetic*

Substances

Core Binding Factor Alpha 2 Subunit
RUNX1 Translocation Partner 1 Protein
RUNX1T1 protein, human
RUNX1 protein, human